Development of a panel of three multiplex allele-specific qRT-PCR assays for quick differentiation of recombinant variants and Omicron subvariants of SARS-CoV-2

Jianguo Li, Zefeng Gao, Jing Chen, Ruiling Cheng, Jiahui Niu, Jialei Zhang, Yang You, Ximei Yuan, Juan Xia, Guoli Mao, Hulong Liu, Yongkang Dong, Changxin WuFrontiers in Cellular and Infection Microbiology 2022 · DOI

TL;DR

This paper presents a new set of three multiplex allele-specific qRT-PCR assays designed for rapid and cost-effective differentiation of SARS-CoV-2 Omicron subvariants (BA.1, BA.2) and recombinant variants (XD, XE). These assays offer high sensitivity, specificity, and clinical accuracy, providing a valuable tool for real-time epidemiological surveillance.

What Problem Does This Paper Address?

The emergence of new SARS-CoV-2 variants, including Omicron subvariants and recombinant strains like XD and XE, poses a significant challenge for public health. Quickly identifying and tracking these variants is crucial for understanding their transmission dynamics, pathogenicity, and the effectiveness of interventions. Traditional methods like whole-genome sequencing are accurate but are time-consuming and expensive, making them impractical for routine, large-scale surveillance. While allele-specific qRT-PCR has shown promise for variant screening, a comprehensive assay that can simultaneously differentiate multiple key Omicron subvariants and recombinant variants was lacking. This paper aims to fill that gap by developing and validating such a multiplex assay.

Methods

The core of this research is the development of three multiplex allele-specific quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) assays. Each assay targets specific mutations that differentiate the variants of interest. The key innovation lies in the multiplexing approach, where each assay uses two parallel reactions: one targeting the "prototype" (wild-type) allele and another targeting the "mutated" allele for a given genetic locus.

The differentiation of variants relies on analyzing the difference in Cycle threshold (Cp) values (ΔCp) between these two parallel reactions. A significant difference in Cp values indicates the presence of the mutated allele, thus identifying a specific variant. The assays were designed to target 12 key differential mutations across viral genes (NSP1, NSP3, NSP6, and Spike).

The development process involved:

  • Viral Genome Sequence Analysis: Analyzing a large dataset of SARS-CoV-2 genomes to identify key differential mutations.
  • Primer and Probe Design: Designing allele-specific primers and probes for each mutation, considering factors like GC content, amplicon size, and melting temperature (Tm).
  • Plasmid Construction and RNA Transcript Preparation: Synthesizing viral gene fragments and creating RNA transcripts to serve as positive controls and for assay validation.
  • Assay Formulation and Optimization: Optimizing reaction mixes and thermocycling conditions for the multiplex qRT-PCR assays.
  • Analytical Validation: Rigorously testing the assays for analytical sensitivity (Limit of Detection - LoD), linear detection range, amplification efficiency, and reproducibility (intra- and inter-assay).
  • Clinical Validation: Evaluating the performance of the developed assays using clinical specimens and comparing the results to Sanger sequencing.

Datasets

The study utilized publicly available SARS-CoV-2 genome sequences from GISAID (Global Initiative on Sharing All Influenza Data) for primer and probe design. For analytical validation, in vitro transcribed RNA of the targeted viral genes was used. For clinical validation, 105 nasopharyngeal swabs from patients were used. The results from the developed assays were compared against those obtained from Sanger sequencing, which served as the gold standard for variant confirmation.

Key Insights and Ideas

  • Multiplexing for Efficiency: The development of three multiplex assays, each targeting multiple mutations, significantly increases throughput and reduces the time and cost compared to individual assays or sequencing.
  • ΔCp as a Variant Signature: The clever use of the difference in Cp values (ΔCp) between prototype and mutated allele reactions provides a robust and interpretable metric for variant identification.
  • Targeting Key Differentiating Mutations: The selection of 12 specific mutations that are known to differentiate Omicron subvariants and recombinant strains is crucial for the assay's specificity and utility.
  • High Analytical Performance: The assays demonstrate excellent analytical characteristics, including very low limits of detection and high amplification efficiencies, suggesting they can reliably detect even low viral loads.
  • Clinical Utility Confirmed: The high concordance with Sanger sequencing in clinical samples validates the practical applicability of these assays for real-world surveillance.

Key Results

The developed panel of three multiplex allele-specific qRT-PCR assays successfully differentiated SARS-CoV-2 recombinant variants (XD and XE) and Omicron subvariants (BA.1 and BA.2).

  • Analytical Sensitivity: Limits of Detection (LoDs) ranged from 2.97 to 27.43 copies per reaction, indicating high sensitivity.
  • Linear Detection Range: Assays showed wide linear detection ranges from 10<sup>7</sup> to 10<sup>0</sup> copies per reaction.
  • Amplification Efficiency: Efficiencies were consistently high, ranging from 82% to 95%.
  • Reproducibility: Excellent intra- and inter-assay reproducibility was observed, with Coefficient of Variations (CVs) below 5%.
  • Specificity: The assays showed no cross-reactivity with other common respiratory viruses and bacteria.
  • Clinical Performance: The assays demonstrated high consistency with Sanger sequencing (99.5%-100%), with sensitivities and specificities for BA.1, BA.2, XD, and XE variants ranging from 92% to 100%.

Limitations and Future Work

  • Potential for Future Mutations: The authors acknowledge that the emergence of new mutations in the primer/probe binding regions could potentially affect assay performance. They mitigated this by selecting unique mutations located away from known polymorphic sites. However, ongoing monitoring and potential assay updates will be necessary.
  • Interpretation Threshold: The study established a ΔCp threshold of >2 for mutation determination, with a recommendation for re-testing if ΔCp ≤ 2. While this threshold was based on observed variations, further refinement might be needed with broader datasets.
  • Future Directions: The paper suggests that allele-specific qRT-PCR is a promising approach for viral mutation screening and can be a foundational technology for developing future variant screening assays. The developed panel provides a valuable tool for rapid differentiation, contributing to effective epidemiological surveillance.

Summary updated

Abstract

Quick differentiation of the circulating variants and the emerging recombinant variants of SARS-CoV-2 is essential to monitor their transmission. However, the widely used gene sequencing method is time-consuming and costly when facing the viral recombinant variants, because partial or whole genome sequencing is required. Allele-specific real time RT-PCR (qRT-PCR) represents a quick and cost-effective method in SNP genotyping and has been successfully applied for SARS-CoV-2 variant screening. In the present study, we developed a panel of 3 multiplex allele-specific qRT-PCR assays targeting 12 key differential mutations for quick differentiation of SARS-CoV-2 recombinant variants (XD and XE) and Omicron subvariants (BA.1 and BA.2). Two parallel multiplex qRT-PCR reactions were designed to separately target the protype allele and the mutated allele of the four mutations in each allele-specific qRT-PCR assay. The variation of Cp values (ΔCp) between the two multiplex qRT-PCR reactions was applied for mutation determination. The developed multiplex allele-specific qRT-PCR assays exhibited outstanding analytical sensitivities (with limits of detection [LoDs] of 2.97-27.43 copies per reaction), wide linear detection ranges (10<sup>7</sup>-10<sup>0</sup> copies per reaction), good amplification efficiencies (82% to 95%), good reproducibility (Coefficient of Variations (CVs) < 5% in both intra-assay and inter-assay tests) and clinical performances (99.5%-100% consistency with Sanger sequencing). The developed multiplex allele-specific qRT-PCR assays in this study provide an alternative tool for quick differentiation of SARS-CoV-2 recombinant variants (XD and XE) and Omicron subvariants (BA.1 and BA.2).
BibTeX
@inproceedings{li2022development,
  author = {Jianguo Li and Zefeng Gao and Jing Chen and Ruiling Cheng and Jiahui Niu and Jialei Zhang and Yang You and Ximei Yuan and Juan Xia and Guoli Mao and Hulong Liu and Yongkang Dong and Changxin Wu},
  title = {{Development of a panel of three multiplex allele-specific qRT-PCR assays for quick differentiation of recombinant variants and Omicron subvariants of SARS-CoV-2}},
  booktitle = {Frontiers in Cellular and Infection Microbiology},
  year = {2022},
  doi = {10.3389/fcimb.2022.953027},
}
Figure